GOSERELIN ACETATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1989)
Entry Type: Protein
Molecule Category: Salt
UNII: 6YUU2PV0U8
Parent Compound: GOSERELIN

Structure
InChI Key IKDXDQDKCZPQSZ-JHYYTBFNSA-N
Smile CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
InChI
InChI=1S/C59H84N18O14.C2H4O2/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38;1-2(3)4/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90);1H3,(H,3,4)/t38-,39-,40-,41-,42-,43-,44-,45+,46-;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C61H88N18O16
Molecular Weight 1329.48
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
AGONIST Gonadotropin-releasing hormone receptor agonist DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Breast Neoplasms 4 D001943 ClinicalTrials
Breast Neoplasms 4 D001943 ClinicalTrials
Infertility 3 D007246 ClinicalTrials
Menopause 3 D008593 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 3 D064129 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Peritoneal Neoplasms 2 D010534 ClinicalTrials
Salivary Gland Neoplasms 2 D012468 ClinicalTrials
Fallopian Tube Neoplasms 2 D005185 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Breast Neoplasms, Male 1 D018567 ClinicalTrials
Metabolic Syndrome 1 D024821 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
18.46
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
8.86
Nervous system disorders
8.17
Musculoskeletal and connective tissue disorders
7.22
Injury, poisoning and procedural complications
6.94
Vascular disorders
6.76
Psychiatric disorders
4.81
Investigations
4.62
Gastrointestinal disorders
4.42
Reproductive system and breast disorders
4.14
Respiratory, thoracic and mediastinal disorders
3.86
Skin and subcutaneous tissue disorders
3.61
Cardiac disorders
3.43
Metabolism and nutrition disorders
2.72
Renal and urinary disorders
2.21

Cross References

Resources Reference
ChEMBL CHEMBL1200501
EPA CompTox DTXSID9046736
FDA SRS 6YUU2PV0U8
PubChem 16052011
SureChEMBL SCHEMBL6094
CONTENTS